Houghton P J, Bailey F C, Houghton J A, Murti K G, Howbert J J, Grindey G B
Department of Biochemical and Clinical Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101-0318.
Cancer Res. 1990 Feb 1;50(3):664-8.
N-(4-Methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (MPCU) is a new agent that exhibits high therapeutic activity against human and rodent tumor models. Initial studies indicated that in vitro [3H]MPCU was concentrated 4- to 6-fold in GC3/c1 human colon adenocarcinoma cells in an azide-sensitive manner. In this study the dependence of uptake and concentrative accumulation of MPCU upon temperature, plasma membrane potential, and the electrochemical potential of mitochondria has been examined. Accumulation and efflux of MPCU were temperature dependent. At 3.6 microM MPCU, initial rates of uptake (15 s) were 1.4, 38.0, and 84.2 pmol/min/10(6) cells at 2 degrees C, 23 degrees C, and 37 degrees C, respectively. The rate of uptake and concentrative accumulation within GC3/c1 cells was not altered in high K+ buffer or by 1 mM ouabain, indicating that plasma membrane potential was not significant in these processes. Concentrative accumulation, but not initial uptake, was inhibited by carbonyl cyanide p-trifluoromethoxyphenylhydrazone, 2,4-dinitrophenol, and sodium azide. Glucose partially antagonized the inhibition of these agents which uncouple oxidative phosphorylation. Oligomycin, an inhibitor of mitochondrial ATP synthase, did not inhibit uptake or concentrative accumulation of MPCU. However, oligomycin in the presence of 2-deoxyglucose significantly inhibited concentrative accumulation of MPCU. These results suggested that concentrative accumulation of MPCU was dependent upon the mitochondrial transmembrane gradient rather than ATP, although direct implication of ATP could not be excluded. To examine which component of this gradient was predominant in causing MPCU sequestration, the ionophores valinomycin and nigericin were used. Valinomycin, which collapses the charge gradient across the mitochondrial matrix membrane, caused only slight inhibition of MPCU accumulation, and the effect was similar at 2 or 10 mumol. In contrast, nigericin (which collapses the pH gradient and increases mitochondrial membrane potential) inhibited by approximately 90% concentrative accumulation of MPCU. These data suggested that MPCU was being concentrated in mitochondria and that this was dependent upon the pH gradient across mitochondrial membrane. In cells exposed to MPCU or the analogue N-(5-indanylsulfonyl)-N'-(4-chlorophenyl)urea, enlargement of mitochondria was observed within 24 h and appeared to be the initial morphological change associated with drug treatment. These results implicate mitochondria as a site of sequestration of diarylsulfonylureas and as a potential site of action.
N-(4-甲基苯基磺酰基)-N'-(4-氯苯基)脲(MPCU)是一种对人类和啮齿动物肿瘤模型具有高治疗活性的新型药物。初步研究表明,体外实验中,[3H]MPCU以叠氮化物敏感的方式在GC3/c1人结肠腺癌细胞中浓缩4至6倍。在本研究中,已检测了MPCU摄取和浓缩积累对温度、质膜电位和线粒体电化学电位的依赖性。MPCU的积累和流出是温度依赖性的。在3.6 microM MPCU时,在2℃、23℃和37℃下,初始摄取率(15秒)分别为1.4、38.0和84.2 pmol/分钟/10(6)个细胞。在高钾缓冲液中或用1 mM哇巴因处理时,GC3/c1细胞内的摄取率和浓缩积累率没有改变,这表明质膜电位在这些过程中并不重要。羰基氰化物对三氟甲氧基苯腙、2,4-二硝基苯酚和叠氮化钠抑制了浓缩积累,但不影响初始摄取。葡萄糖部分拮抗了这些使氧化磷酸化解偶联的药物的抑制作用。线粒体ATP合酶抑制剂寡霉素不抑制MPCU的摄取或浓缩积累。然而,在2-脱氧葡萄糖存在下,寡霉素显著抑制了MPCU的浓缩积累。这些结果表明,MPCU的浓缩积累依赖于线粒体跨膜梯度而非ATP,尽管不能排除ATP的直接作用。为了研究该梯度的哪个成分在导致MPCU隔离中起主要作用,使用了离子载体缬氨霉素和尼日利亚菌素。缬氨霉素可消除线粒体基质膜上的电荷梯度,仅对MPCU积累产生轻微抑制,在2或10 μmol时效果相似。相比之下,尼日利亚菌素(可消除pH梯度并增加线粒体膜电位)抑制了约90%的MPCU浓缩积累。这些数据表明,MPCU在线粒体中被浓缩,且这依赖于线粒体膜上的pH梯度。在暴露于MPCU或类似物N-(5-茚满基磺酰基)-N'-(4-氯苯基)脲的细胞中,24小时内观察到线粒体增大,这似乎是与药物处理相关的初始形态学变化。这些结果表明线粒体是二芳基磺酰脲类药物的隔离位点和潜在的作用位点。